How long is a typical GHK-Cu cycle?
Preclinical GHK-Cu research protocols typically run 4-12 weeks of continuous administration, with the specific length depending on the dermal-research or skin-regeneration endpoint being studied. Cosmetic-ingredient-style protocols sometimes use cycle-on/off patterns; systemic research typically uses continuous administration across the full protocol period.
What the research literature says
The GHK-Cu protocol-length framework is informed by the Pickart synthesis literature spanning multiple tissue contexts. The Pickart oxidative-stress review (PMID 22666519), the skin-regeneration synthesis (PMID 26236730), and the 2018 regenerative-actions review (PMID 29986520) all reference multi-week protocol lengths consistent with the 4-12 week range. The Kang keratinocyte work characterised cellular responses that develop across weeks of consistent administration (PMID 19319546).
Dermal-research protocols often use shorter time frames (4-6 weeks) because the dermal-tissue turnover cycle supports observable endpoints within this window. Hair-follicle research extends to longer protocols (12+ weeks) because the hair-growth cycle operates on slower time scales. Cognitive-aging research (per the Pickart cognitive-health synthesis) typically uses much longer protocols extending beyond the typical research-supply protocol length.
The Conato coordination-chemistry framework (PMID 11325542) supports the protocol-design framework by establishing the Cu(II) chelation stability that underlies sustained compound activity across the multi-week dosing period — the compound’s structural integrity is maintained across the typical in-use stability window.
Why this matters in research context
The 4-12 week protocol length is the operational anchor for most GHK-Cu research protocols. Dermal applications often use the shorter end of the range; hair-follicle and cognitive applications use the longer end. Cycle on/off practice is less standardised than for the GH-axis compounds — most published GHK-Cu protocols use continuous administration across the full protocol period rather than alternating on/off periods.
Related compounds
- GHK-Cu 50mg — the compound covered by this answer
- Glow Blend — combined-formulation including GHK-Cu
Related research questions
References
- Conato C et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta 2001;1526(2):199-210. [PMID 11325542]
- Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res 2009;301(4):301-306. [PMID 19319546]
- Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev 2012;2012:324832. [PMID 22666519]
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015;2015:648108. [PMID 26236730]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. GHK-Cu is sold strictly as a research-grade reagent for laboratory and bench research applications.